$0.74
7.13% yesterday
NYSE, Nov 25, 09:50 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock price

$0.70
+0.01 1.21% 1M
-0.02 3.27% 6M
-0.01 1.84% YTD
-0.06 8.36% 1Y
-3.00 80.98% 3Y
-4.43 86.28% 5Y
-3.17 81.81% 10Y
NYSE, Closing price Mon, Nov 25 2024
-0.09 11.35%
ISIN
US9286611077
Symbol
VNRX
Sector

Key metrics

Market capitalization $65.22m
Enterprise Value $64.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 50.05
P/S ratio (TTM) P/S ratio 50.56
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 97.50%
Revenue (TTM) Revenue $1.29m
EBIT (operating result TTM) EBIT $-29.98m
Free Cash Flow (TTM) Free Cash Flow $-14.48m
Cash position $5.41m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 42.81
EV/Sales forward 42.38
Short interest 0.61%
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a VolitionRX forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a VolitionRX forecast:

Buy
75%
Hold
25%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.29 1.29
98% 98%
100%
- Direct Costs 1.34 1.34
1% 1%
104%
-0.06 -0.06
92% 92%
-5%
- Selling and Administrative Expenses 13 13
13% 13%
1,039%
- Research and Development Expense 15 15
15% 15%
1,177%
-29 -29
16% 16%
-2,220%
- Depreciation and Amortization 1.34 1.34
1% 1%
104%
EBIT (Operating Income) EBIT -30 -30
15% 15%
-2,324%
Net Profit -30 -30
12% 12%
-2,316%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
Seeking Alpha
11 days ago
VolitionRx Limited (NYSE:VNRX ) Q3 2024 Earnings Conference Call November 15, 2024 8:30 AM ET Company Participants Louise Batchelor - Chief Marketing & Communications Officer Tom Butera - CEO, Volition Veterinary Diagnostic Development Andrew Retter - Chief Medical Officer Terig Hughes - CFO Cameron Reynolds - President & CEO Conference Call Participants Jason Kolbert - D. Boral Capital Ilya Zu...
Neutral
PRNewsWire
12 days ago
Conference call to discuss financial and operational results scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
Neutral
PRNewsWire
18 days ago
Conference call to take place on Friday, November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 110
Founded 1998
Website www.volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today